Business Wire

CGTN: China Outlines Four-point Proposal for the Future of APEC

Share

With the world and the Asia-Pacific region undergoing profound changes, China has called for joint efforts to build an Asia-Pacific community with a shared future featuring openness, inclusiveness, innovation-driven growth, greater connectivity, and mutually beneficial cooperation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201121005045/en/

Read the original article here.

China highly values the role of the Asia-Pacific Economic Cooperation (APEC) and will continue to support the development of the organization, President Xi Jinping said on Friday when addressing the APEC Economic Leaders' Meeting in Beijing via video link.

Established in 1989, APEC has become an important platform to facilitate economic cooperation among 21 economies in the Asia-Pacific region.

However, the region is currently facing challenges such as backlashes against economic globalization, rising unilateralism, and protectionism, as well as the fallout from the COVID-19 pandemic.

"For the first time in decades, the Asia-Pacific as a whole registered negative economic growth," Xi said. "Protecting people's health and reviving the economy are two formidable tasks we have to take on."

The Chinese president outlined a four-point proposal for the future of Asia-Pacific cooperation.

Read more:

China to boost economic growth through innovation and opening-up, nurturing joint development in the Asia-Pacific region

Foreign leaders urge APEC members to advocate multilateral trade

Open and inclusive

"First, we need to stay open and inclusive," Xi said. "It is important that the Asia-Pacific should remain the bellwether in safeguarding peace and stability, upholding multilateralism, and fostering an open world economy."

He called for further efforts to promote regional economic integration for the early realization of a Free Trade Area of the Asia-Pacific (FTAAP).

The FTAAP proposal was initiated in 2004 and written into the declaration of the APEC meeting in 2006. During the 2014 APEC meeting in Beijing, the initiative made a breakthrough, with APEC members unanimously adopting the FTAAP Beijing Roadmap to achieve the goal.

The recent signing of the Regional Comprehensive Economic Partnership (RCEP) free trade agreement was viewed as a significant step toward the establishment of the FTAAP.

The pact was signed on Sunday among its 15 participating countries, including the 10 member countries of the Association of Southeast Asian Nations and China, Japan, South Korea, Australia, and New Zealand.

"China welcomes the signing of the RCEP and will favorably consider joining the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP)," Xi said.

Effective since December 30, 2018, the CPTPP is a trade pact among 11 countries, including Japan, Canada, Australia, Singapore, Chile, and Mexico, whose aggregate gross domestic product accounts for 13 percent of the world economy.

Efforts should be made to "promote free and open trade and investment, and make economic globalization more open, inclusive, balanced and beneficial to all," he said.

Innovation-driven growth

"Second, we need to pursue innovation-driven growth," Xi said, calling for improving the digital infrastructure and bridging the digital divide in the region.

Asia-Pacific economies should "foster an open, fair, equitable and non-discriminatory environment for businesses," he stressed.

Digital technologies should play a bigger role in facilitating experience sharing on epidemic control, boosting economic recovery, and eradicating poverty in the region, he suggested.

The emphasis on innovation is in line with China's own priorities on development. The country vows to uphold the central role of innovation in its modernization drive and take self-reliance in science and technology as a strategic underpinning for national development, according to a newly unveiled blueprint for its development in the next 15 years.

"Third, we need to enhance connectivity," Xi added, calling connectivity a "vital basis of regional economic integration."

He pledged active efforts to set up "green lanes" with other parties to help make customs clearance more efficient during the pandemic and stabilize industrial and supply chains in the region and beyond.

The Chinese president also expressed the hope to work with other parties to build a high-quality Belt and Road.

Not a 'zero-sum political game'

"Fourth, we need to promote mutually beneficial cooperation," he said, stressing that economies in the region are highly complementary to each other.

"Our economic cooperation has never been a zero-sum political game in which one's loss is another's gain," he said. "Rather, our cooperation has provided us with a development platform to ensure what we each do can be mutually reinforcing and beneficial to all."

Xi called for advancing research of the development of COVID-19 vaccines and make them a global public good affordable in developing countries.

At the virtual meeting hosted by Malaysia, APEC launched a Post-2020 vision – the APEC Putrajaya Vision 2040, which is the bloc's new long-term blueprint for future cooperation. It laid out three economic drivers: "trade and investment," "innovation and digitalization," and "strong, balanced, secure, sustainable and inclusive growth."

The 2020 Kuala Lumpur Declaration was also issued at the meeting, calling for solidarity to defeat the pandemic and revive the economy across the region.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye